MedTrace Logo

Selective Targeting of Adjuvant Therapy for Endometrial Cancer (STATEC)

NCT02566811 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2019-09-30

No results posted yet for this study

Summary

The primary aim of this trial is to determine whether lymphadenectomy, used to restrict adjuvant therapy (other than vaginal brachytherapy) to node positive women, results in a non-inferior survival as compared to adjuvant therapy given to all women with high risk apparent stage 1 endometrial cancer.

Conditions

Interventions

PROCEDURE

Abdominal surgery

Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required

PROCEDURE

Lymphadenectomy

Bilateral pelvic and para-aortic lymph node dissection

Sponsors & Collaborators

  • University College, London

    lead OTHER

Principal Investigators

  • Tim Mould · University College London Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-12
Primary Completion
2019-08-14
Completion
2019-08-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02566811 on ClinicalTrials.gov